DEFA14A: Avid Bioservices Urges Stockholders to Approve Acquisition by GHO and Ampersand Following ISS and Glass Lewis Recommendations

Avid Bioservices encourages stockholders to vote in favor of the proposed acquisition by GHO Capital Partners and Ampersand Capital Partners, supported by recommendations from ISS and Glass Lewis.

Summary

• Avid Bioservices is urging its stockholders to vote in favor of the proposed acquisition by GHO Capital Partners and Ampersand Capital Partners.
• Leading independent proxy advisory firms, Institutional Shareholder Services (ISS) and Glass Lewis & Co., have recommended that Avid stockholders vote FOR the transaction.
• ISS stated that the sales process was thorough, shareholders are receiving a premium, the valuation supports the premium, and the cash consideration provides liquidity and certainty.
• The Avid Board of Directors unanimously recommends that stockholders vote FOR the proposed transaction.
• The company has filed a proxy statement with the SEC and mailed it to stockholders.
• Stockholders are urged to read the proxy statement and other relevant documents filed with the SEC.
• Moelis & Company LLC is serving as exclusive financial advisor to Avid, and Cooley LLP is serving as legal counsel.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the document highlights the support from ISS and Glass Lewis for the acquisition, indicating a favorable outcome for stockholders. However, the presence of forward-looking statements and associated risks tempers the overall sentiment.

Positives

• Independent proxy advisory firms ISS and Glass Lewis recommend voting in favor of the acquisition.
• ISS highlights a premium for shareholders and certainty of value through cash consideration.
• The Avid Board of Directors unanimously supports the transaction.
• The sales process was sufficiently thorough.

Risks

• The timing, receipt, and terms of required governmental and regulatory approvals could delay or cause abandonment of the transaction.
• An event, change, or circumstance could lead to termination of the merger agreement.
• Stockholders may not approve the proposed transaction.
• The parties may not be able to satisfy the conditions to the transaction in a timely manner.
• The transaction could disrupt management time from ongoing business operations.
• Announcements relating to the transaction could adversely affect the market price of Avid's common stock.
• Unexpected costs or expenses could result from the transaction.
• Litigation relating to the transaction could arise.
• The transaction and its announcement could adversely affect the company's ability to retain and hire key personnel and maintain relationships with stakeholders.

Future Outlook

The document contains forward-looking statements regarding the proposed sale of Avid to GHO and Ampersand, subject to various risks and uncertainties.

Management Comments

• Nick Green, president and CEO of Avid Bioservices, said, 'We are pleased that ISS and Glass Lewis recognize the premium value of the GHO and Ampersand transaction for Avid stockholders, as well as the process run by our Board of Directors to ensure we are maximizing value.'
• Nick Green also stated, 'We encourage our stockholders to vote FOR our transaction with GHO and Ampersand today.'

Industry Context

This announcement reflects the ongoing trend of consolidation in the CDMO (Contract Development and Manufacturing Organization) industry, with private equity firms like GHO and Ampersand seeking to acquire established players like Avid Bioservices to capitalize on the growing demand for biologics manufacturing.

Comparison to Industry Standards

• It is difficult to compare this announcement to industry standards as it is a recommendation to vote for an acquisition.
• However, the involvement of ISS and Glass Lewis is standard practice in mergers and acquisitions to provide independent assessments to shareholders.
• Comparable companies in the CDMO space include Lonza, Catalent, and Thermo Fisher Scientific, but their situations and valuations may differ significantly.

Stakeholder Impact

• Shareholders are expected to receive a premium for their shares if the transaction is approved.
• Employees may experience changes in their roles and responsibilities following the acquisition.
• Customers can expect continuity of services, but potential changes in management and strategy.
• Vendors and partners may need to adjust to new ownership and management structures.

Next Steps

• Stockholders need to vote on the proposed transaction.
• The company awaits required governmental and regulatory approvals.
• The special meeting of stockholders will be held on January 30, 2025.

Key Dates

Keywords

acquisition, Avid Bioservices, GHO Capital Partners, Ampersand Capital Partners, ISS, Glass Lewis, proxy statement, stockholders, CDMO, merger